Online inquiry

IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3064MR)

This product GTTS-WQ3064MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TFPI gene. The antibody can be applied in Hemophilia B research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001032281.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7035
UniProt ID P10646
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3064MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2464MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 181
GTTS-WQ13453MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PRS-343
GTTS-WQ6190MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CP-870893
GTTS-WQ205MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 13C5.5
GTTS-WQ11193MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI0562
GTTS-WQ297MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ4307MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIVV009
GTTS-WQ6948MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ESBA-1008
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW